Tracleer receives label extension in the US for the treatment of patients with mildly symptomatic WHO Functional Class II PAH

10 August 2009 - Actelion Ltd announced today that the U.S. FDA has approved the company's supplemental New Drug Application (sNDA) for Tracleer® (bosentan) to treat patients with mildly symptomatic WHO Functional Class II (FC II) pulmonary arterial hypertension (PAH).

The details can be read here.